Stéphanie TCHERNY-LESSENOT

Head of Benefit-Risk Evaluation
Sanofi, France

Poster(s):

• (A-048) Dupilumab Demonstrates a Higher Benefit-risk Score Compared with Upadacitinib: A Structured Benefit-risk Assessment of the HEADS UP Trial
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (A-025) Is there an impact of menstrual cycles on chronic diseases outcomes?
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (A-022) Opening the DOOR for Patient-Centric Benefit-risk Evaluation:Highlights from the CIOMS Benefit-risk Working Group
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (SLB-013) Structured benefit-risk assessment for isatuximab in transplant-ineligible newly diagnosed multiple myeloma patients
  Monday, August 25, 2025

  11:45 AM - 12:45 PM ET